Molecular Devices Begins Shipping SynchroMax(TM) ET Plate Handling Robot

Molecular Devices Begins Shipping SynchroMax(TM) ET Plate
Handling Robot 


SUNNYVALE, Calif., July 15  /PRNewswire-FirstCall/ -- Molecular Devices
Corporation (NASDAQ:MDCC) today announced the first shipment of the SynchroMax
ET Plate Handling Robot -- the latest addition to its line of microplate
readers and liquid handling systems. The SynchroMax ET Plate Handler provides
walk-away automation for ELISA workstations and cell-based screening units
which include a Molecular Devices' SpectraMax(R) or Gemini microplate reader,
AquaMax(R) dispenser or Embla washer. ELISA and cell-based screening assays
make up the largest application segments for life sciences research. With the
SynchroMax ET, researchers can run up to 320 microplates uninterrupted in 96-,
384- or 1536-well formats, improving efficiency and freeing up valuable
research time.

A complete, automated workstation can be purchased directly from Molecular
Devices, eliminating the need to combine instrumentation from multiple vendors.
The configuration and installation of the assay workstation by qualified
Molecular Devices onsite application scientists provides optimal data quality
and throughput.

Molecular Devices' SpectraMax multimode detectors are a standard in academic,
biotech and pharmaceutical industry laboratories for life sciences research.
Together with SpectraTest(TM) instrument validation tools and SoftMax(R) Pro
software data analysis and compliance capabilities, migrating automated assay
workstations to the GLP/cGMP and FDA 21 CFR Part 11 environment can be achieved
quickly.

Molecular Devices Corporation is a leading supplier of high-performance
bioanalytical measurement systems that accelerate and improve drug discovery
and other life sciences research.  The Company's systems and consumables enable
pharmaceutical and biotechnology companies to leverage advances in genomics,
proteomics and combinatorial chemistry by facilitating the high-throughput and
cost-effective identification and evaluation of drug candidates.  The Company's
solutions are based on its advanced core technologies that integrate its
expertise in engineering, molecular and cell biology and chemistry.  Molecular
Devices enables its customers to improve research productivity and
effectiveness, which ultimately accelerates the complex process of discovering
and developing new drugs.

This press release contains "forward-looking" statements, including statements
related to the prospects for or potential customer use of the SynchroMax(TM) ET
Plate Handling Robot. Any statements contained in this press release that are
not statements of historical fact may be deemed to be forward-looking
statements. Words such as "believes," "anticipates," "plans," "expects,"
"will," and similar expressions are intended to identify forward-looking
statements. There are a number of important factors that could cause the
results of Molecular Devices Corporation to differ materially from those
indicated by these forward-looking statements, including, among others, risks
detailed from time to time in the Company's SEC reports, including its Annual
Report on Form 10-K for the year ended December 31, 2003, as amended, and its
quarterly report on Form 10-Q for the quarter ended March 31, 2004. Molecular
Devices Corporation does not undertake any obligation to update forward-looking
statements. 

DATASOURCE: Molecular Devices Corporation



CONTACT:  Tim Harkness of Molecular Devices Corporation, [phone]



Web site:  http://www.moleculardevices.com/ 

Copyright